VCYT Stock Analysis: Buy, Sell, or Hold?
VCYT - Veracyte, Inc.
$30.35
0.34 (1.13%)
ā²
5d:
-9.51%
30d:
-17.05%
90d:
-28.57%
HOLD
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 06, 2026
Get Alerted When VCYT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
š HOLD: VCYT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
š HOLD: VCYT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$56.33
Based on 5.7% avg growth
INTRINSIC VALUE TODAY
$34.97
13.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 24.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: VCYT is currently trading at $30.35, which is considered oversold relative to its 30-day fair value range of $32.20 to $36.14. From a valuation perspective, the stock is trading at a discount (Forward PE: 16.9) compared to its historical average (24.1). Remarkably, the market is currently pricing in an annual earnings decline of 11.1% over the next few years. This pessimistic expectation contrasts with the company's recent 712.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, VCYT is in a strong downtrend. The price is currently testing key support at $29.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: VCYT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $47.50 (+58.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, VCYT is in a strong downtrend. The price is currently testing key support at $29.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: VCYT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $47.50 (+58.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$32.20 -
$36.14
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 58.3% below Wall St target ($47.50)
- CAUTION: 5-day price weakness (-9.5%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$32.20 -
$36.14
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$29.46
Resistance Level
$34.18
Current Trend
Strong Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.94
Wall Street Target
$47.50
(+58.3%)
Revenue Growth (YoY)
18.5%
Earnings Growth (YoY)
712.0%
Profit Margin
12.8%
Valuation Discount vs History
-11.1% cheaper
PE vs Historical
16.9 vs 24.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-11.1%
(market-implied from PE analysis)
1-Year Target
$27.01
(-10%)
2-Year Target
$24.31
(-19%)
3-Year Target
$21.88
(-27%)
3-Yr Target (if PE normalizes)
(PE: 17ā24)
$31.13
(+4%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 7.4%)
$49.18
(+64%)
Base:
(SPY PE: 16.9, Growth: 7.4%)
$37.18
(+24%)
Bear:
(PE: 14.4, Growth: 7.4%)
$31.61
(+5%)
š
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (39x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 38.83 | Current EPS (TTM): $0.82
Bull Case
$70.05
(+109%)
Analyst growth 100.0%, PE expands to 42.7
Base Case
$63.68
(+90%)
Market implied 100.0%, PE stable at 38.8
Bear Case
$21.65
(-35%)
Severe decline -20.0%, PE contracts to 33.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
š”
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 16.9 to 24.1
Stabilization Target:
$42.71
(+42.3%)
PE Expansion Potential:
+42.3%
Share & Embed Analysis
Last updated: March 30, 2026 1:52 PM ET
Data refreshes hourly during market hours. Next update: 2:52 PM
Data refreshes hourly during market hours. Next update: 2:52 PM
š„ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VCYT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
19
Sells
Net
INSIDERS SELLING
Recent Transactions
John Leite
SELL
5260 shares
2026-03-04
Marc Stapley
SELL
45523 shares
2026-03-04
Rebecca Chambers
SELL
18341 shares
2026-03-04
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientificā¦ |
STRONG BUY
31 analysts |
$664 | 60 BUY |
|
EXAS
EXACT Sciences Corporatiā¦ |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
26 analysts |
$265 | 61 BUY |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$133 | 56 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$261 | 54 HOLD |
